Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Income towards Parent Company: 2009-2025

Historic Income towards Parent Company for Cumberland Pharmaceuticals (CPIX) over the last 17 years, with Sep 2025 value amounting to -$1.9 million.

  • Cumberland Pharmaceuticals' Income towards Parent Company fell 26.81% to -$1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.3 million, marking a year-over-year increase of 69.22%. This contributed to the annual value of -$6.4 million for FY2024, which is 1.78% down from last year.
  • As of Q3 2025, Cumberland Pharmaceuticals' Income towards Parent Company stood at -$1.9 million, which was down 165.10% from -$735,207 recorded in Q2 2025.
  • Cumberland Pharmaceuticals' 5-year Income towards Parent Company high stood at $1.2 million for Q1 2025, and its period low was -$6.3 million during Q4 2023.
  • Its 3-year average for Income towards Parent Company is -$1.3 million, with a median of -$1.1 million in 2024.
  • In the last 5 years, Cumberland Pharmaceuticals' Income towards Parent Company plummeted by 1,204.25% in 2024 and then skyrocketed by 165.61% in 2025.
  • Cumberland Pharmaceuticals' Income towards Parent Company (Quarterly) stood at $503,318 in 2021, then crashed by 588.70% to -$2.5 million in 2022, then plummeted by 156.21% to -$6.3 million in 2023, then spiked by 69.82% to -$1.9 million in 2024, then fell by 26.81% to -$1.9 million in 2025.
  • Its last three reported values are -$1.9 million in Q3 2025, -$735,207 for Q2 2025, and $1.2 million during Q1 2025.